I'm not one to focus on management, as much as I am interested in the value of the science, and it's competitive standing. To someone less experienced, the article raises concerns, if indeed, we have any substantive competitive advantage, specifically, against the stats they're reporting? I came into this with the knowledge, that a GBM diagnosis rarely offers any hope of survival beyond some months. That any slight improvement in OS is strong grounds for approval. How is it, that these other approved drugs seem to have enjoyed a clearer, less tortured road to approval. The treatment of GBM is unequivocally an unmet need. Meanwhile, we've become programmed to standby, be patient, as we must wait for a tail to mature. It doesn't feel like it's adding up.
Market Data 
Markets 
AI
